文献速递肝病

非酒精性脂肪性肝病患者中适度饮酒与组织学脂肪变性和脂肪性肝炎改善较少相关

Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-14

在非酒精性脂肪性肝病(NAFLD)成人中,基于NASH临床研究网络配对肝活检的纵向分析显示,适度饮酒者(≤2杯/天)相比不饮酒者脂肪变分级平均降幅更小(0.30 vs 0.49,P=0.04),天冬氨酸转氨酶平均变化为升高2 U/L vs 降低7 U/L(P=0.04),且校正后NASH缓解的比值比更低(OR 0.32,95%CI 0.11-0.92,P=0.04)。

要点

  • 适度饮酒者脂肪变分级平均降低0.30,不饮酒者降低0.49(P=0.04)。
  • 适度饮酒者天冬氨酸转氨酶平均升高2 U/L,不饮酒者降低7 U/L(P=0.04)。
  • 校正后适度饮酒者NASH缓解的OR为0.32(95%CI 0.11-0.92,P=0.04)。

核心结论

  • 在未接受药物治疗的NAFLD患者纵向肝活检分析中,相比不饮酒,适度饮酒与脂肪变和天冬氨酸转氨酶水平改善较少以及NASH缓解比值比更低相关。

研究设计与样本

  • NASH临床研究网络成年参与者中21岁及以上、未接受药物治疗、有2次及以上肝活检且初次活检前2年内有饮酒数据者。
  • 共285名参与者(82%白人,70%女性,平均年龄47岁),其中168名(59%)为适度饮酒者(≤2杯/天),其余117名不饮酒。
  • 饮酒情况通过酒精使用障碍识别测试和Skinner终生饮酒史问卷评估,随访时询问饮酒频率、典型日饮酒量和重度饮酒频率。
  • 采用协方差分析评估基线饮酒状态与纤维化分期、NASH组织学、NAFLD活动评分及其各组分变化的关系,采用校正logistic回归评估饮酒状态变化与组织学变化的关系。

主要发现

  • 基线时适度饮酒者中白人比例更高(86% vs 76%非白人,P=0.04),确诊NASH比例更低(57% vs 74%无NASH,P=0.01)。
  • 两次活检间平均随访47个月,不饮酒者脂肪变分级平均降低0.49,适度饮酒者降低0.30(P=0.04)。
  • 不饮酒者天冬氨酸转氨酶平均降低7 U/L,适度饮酒者平均升高2 U/L(P=0.04)。
  • 校正分析中,适度饮酒者相比不饮酒者NASH缓解的比值比显著更低(校正OR 0.32,95%CI 0.11-0.92,P=0.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cross-sectional studies of patients with nonalcoholic fatty liver disease (NAFLD) have reported a lower prevalence of severe disease among modest drinkers compared with nondrinkers. We collected data from adult participants in the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network to evaluate the longitudinal association between modest use of alcohol and histology findings in patients with NAFLD, using paired liver biopsies collected more than 1 year apart. METHODS: We studied NASH Clinical Research Network participants 21 years or older, not receiving pharmacologic therapy, from whom 2 or more liver biopsies and data on alcohol use within 2 years of the initial biopsy were available. Alcohol consumption was evaluated at study entry using the Alcohol Use Disorders Identification Test and Skinner Lifetime Drinking History questionnaires. At each follow-up visit participants were asked about alcohol use frequency, number of drinks on a typical day, and frequency of heavy drinking. The association between baseline drinking status and changes in fibrosis stage, NASH histology, and the NAFLD Activity Score and its individual components were evaluated by analysis of covariance. The association between change in drinking status and change in histology was evaluated using adjusted logistic regression. RESULTS: Of 285 participants (82% white, 70% female, mean age, 47 y) meeting entry criteria, 168 (59%) were modest alcohol users (≤2 drinks/d) and the remaining 117 were abstinent. At baseline, a higher proportion of modest alcohol users were white (86% vs 76% nonwhite) (P = .04) and a lower proportion of modest alcohol users were diagnosed with definite NASH (57% vs 74% without NASH; P = .01). During a mean follow-up period of 47 months between biopsies, nondrinkers had a greater mean reduction in steatosis grade (reduction, 0.49) than modest drinkers (reduction, 0.30; P = .04) and a greater reduction in mean level of aspartate transaminase (reduction, 7 U/L vs an increase of 2 U/L in modest drinkers; P = .04). Modest drinkers had significantly lower odds of NASH resolution compared with nondrinkers (adjusted odds ratio, 0.32; 95% CI, 0.11-0.92; P = .04) on adjusted analysis. CONCLUSIONS: In a longitudinal analysis of liver biopsies from patients with NAFLD not receiving pharmacologic therapy, modest alcohol use was associated with less improvement in steatosis and level of aspartate transaminase, as well as lower odds of NASH resolution, compared with no use of alcohol.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ajmera V, Belt P, Wilson LA, et al. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol. 2018. PMID: 29378307. doi:10.1016/j.cgh.2018.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。